| Name | Title | Contact Details |
|---|
Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences. The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company’s deep expertise in DNA. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.
Defyrus Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Checkerspot is a design-centric materials company enabling ultra-high performance consumer products.
Palladio Biosciences, Inc., a private, venture capital-backed biotech company, was founded in 2015 to develop transformative medicines for orphan diseases of the kidney.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases.